Develops long-acting peptide therapies for endocrine and metabolic diseases including hypoparathyroidism and obesity.
Develops long-acting peptide therapies for endocrine and metabolic diseases including hypoparathyroidism and obesity.
Has no product to sell, so it is funded by money raised from investors, and any future income would come from selling its own drugs or licensing them to a larger drugmaker. Its platform engineers peptides to be dosed less often, such as once weekly. It listed in 2024.
Moat: none (IP / patents). Clinical-stage biotech with proprietary long-acting peptide chemistry but no approved products yet.
Headquarters: Carmel, Indiana, US · Founded: 2019 · Employees: 63
Size MBX Biosciences (MBX) is a United States Health Care company (Biotechnology) with a market value of $2.65B, the 1615th largest of 3,085 United States companies the cockpit tracks. Shares closed at $53.42 on 18 Nov 2026.
Performance Over six months the shares gained 70.0%, against -2.0% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Short interest Short interest is 8.9% of the free float (30 Oct 2026).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$343,000 | -$248,000 | -$244,000 | -$157,000 | -$56,000 |
| EBITDA | -$160M | -$97.8M | -$68.0M | -$35.2M | -$25.1M |
| Net income | -$145M | -$87.0M | -$61.9M | -$32.6M | -$26.1M |
| Free cash flow | -$99.3M | -$81.9M | -$55.6M | -$32.1M | -$23.6M |
| Capital expenditure | $3.32M | $1.93M | $874,000 | $129,000 | $441,000 |
| Total debt | $3.29M | $598,000 | $213,000 | $518,000 | $527,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| MBX Biosciences MBX | $2.65B | +70% | n/a | n/a | n/a | n/a |
| Ascendis Pharma A/S ASND | $16.9B | +12% | +94% | 18% | 11.7× | 19.2% |
| Novo Nordisk A/S NOVO-B.CO | $177B | -6% | +6% | 48% | 3.9× | -0.5% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 15.6× | 6.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MBX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.1% | -2.6% | 10th highest of 21 |
| 6-month return | +70.0% | -2.0% | 3rd highest of 21 |
| Distance from 52-week high | -26.5% | -30.1% | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| MBX Biosciences MBX | United States | $2.65B | +70% | n/a | n/a | n/a | n/a | n/a |
| HLB 028300.KS | South Korea | $2.69B | -49% | +26% | -96% | 38.7× | n/a | n/a |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.72B | -7% | +20% | -3% | 5.9× | n/a | n/a |
| Xencor XNCR | United States | $2.58B | +204% | +34% | -73% | 11.7× | n/a | n/a |
| Xiamen Amoytop Biotech 688278.SS | China | $2.56B | -27% | +18% | 27% | 4.3× | -0.6% | +36.0% |
| Zai Lab 9688.HK | Hong Kong | $2.79B | +23% | 0% | -63% | 5.4× | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.82B | +23% | -8% | 18% | 2.6× | -4.3% | +27.4% |
| Walvax Biotechnology 300142.SZ | China | $2.48B | -26% | -23% | 5% | 9.4× | 29.5% | -3.8% |
| XtalPi 2228.HK | Hong Kong | $2.87B | -34% | +4% | -127% | 21.3× | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.94B | +68% | +37% | 21% | 13.2× | n/a | n/a |
| Denali Therapeutics DNLI | United States | $2.95B | -2% | n/a | -2,488% | 115.4× | n/a | n/a |
| Dyne Therapeutics DYN | United States | $2.97B | -10% | n/a | n/a | n/a | n/a | n/a |
| Telix Pharmaceuticals TLX.AX | Australia | $2.99B | -2% | +27% | -1% | 3.8× | n/a | n/a |
| ADMA Biologics ADMA | United States | $3.01B | +58% | +6% | 45% | 6.0× | -0.8% | +64.6% |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.33B | -59% | 0% | -25% | 19.4× | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.27B | -34% | -58% | -475% | 17.6× | n/a | n/a |
| Xeris Biopharma XERS | United States | $3.10B | +173% | +38% | 13% | 8.7× | 29.5% | +70.2% |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.26B | +31% | +223% | 64% | n/a | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +51% | +8% | 19% | 5.0× | 13.4% | +44.5% |
| SKBS 302440.KS | South Korea | $2.25B | -12% | +11% | -23% | 4.3× | n/a | n/a |
| Pharvaris PHVS | United States | $2.21B | +7% | n/a | n/a | n/a | n/a | n/a |